Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
By integrating Rockwell Automation’s FactoryTalk Optix, NKP Pharma has achieved compliance with USFDA 21 CFR Part 11
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Findings likely to generate hypotheses about potential new uses of drugs
Subscribe To Our Newsletter & Stay Updated
